Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia
- 8 May 2008
- journal article
- Published by Springer Nature in Leukemia
- Vol. 22 (11) , 2127-2128
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Pathologic effects of testosterone deprivationCurrent Opinion in Urology, 2007
- Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trialBlood, 2007
- Testosterone Activates Mitogen-Activated Protein Kinase via Src Kinase and the Epidermal Growth Factor Receptor in Sertoli CellsEndocrinology, 2007
- Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetBlood, 2006
- Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML)Critical Reviews in Oncology/Hematology, 2006
- Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal TumorJournal of Korean Medical Science, 2005
- Gynaecomastia in men with chronic myeloid leukaemia after imatinibThe Lancet, 2003
- Expression of Platelet-Derived Growth Factor-A (PDGF-A), PDGF-B, and PDGF Receptor-α and -β during Human Testicular Development and DiseaseThe Journal of Clinical Endocrinology & Metabolism, 2002